Search | Clinical Trials Finder

Conditions: Aerosol Containment, Aerosol Generating Procedure
Interventions: Novel isolation device to contain aerosol; Device
Lead sponsor: John Shin; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ventral Hernia
Interventions: Strattice Reconstructive Tissue Matrix (Hernia Repair), Proceed Surgical Mesh (Hernia repair); Device
Lead sponsor: LifeCell; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: New Orleans, Louisiana • Baltimore, Maryland • West Roxbury, Massachusetts + 8 more

Conditions: Epilepsy
Interventions: RNS® System implantation, RNS® System responsive stimulation; Procedure · Device
Lead sponsor: NeuroPace; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 12
States / cities: Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more

Conditions: Cardiovascular Disease, Vitamin D Deficiency
Interventions: Vitamin D3, Placebo; Dietary Supplement
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Congenital Heart Defect, Executive Function, Children, Neurodevelopmental Disorders, Working Memory, Infant Open Heart Surgery
Interventions: Cogmed Working Memory Training; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 7 Years to 12 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastrointestinal Neoplasms
Interventions: Risvutatug Rezetecan, Drug 1, Drug 2, Drug 3, Drug 4; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Los Alamitos, California • Los Angeles, California • Santa Monica, California + 8 more

Conditions: Morbid Obesity, Cardiovascular Disease, Fatty Acid Levels
Interventions: Bariatric Surgery; Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Congenital Bleeding Disorder, Haemophilia B
Interventions: nonacog beta pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 13 Years to 70 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Appendicitis
Interventions: Operative management, Drainage or antibiotics; Procedure · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, HER2/Neu Negative, Invasive Breast Carcinoma
Interventions: Laboratory Biomarker Analysis, Talazoparib; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Pain, Cesarean Delivery
Interventions: NSS-2-Bridge; Device
Lead sponsor: Grace Lim, MD, MS; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: propanolol; Drug
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Imaged Breast Abnormalities
Interventions: Not listed
Lead sponsor: Intact Medical Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 24
States / cities: Little Rock, Arkansas • Indio, California • Long Beach, California + 20 more

Conditions: Postsurgical Pain Management
Interventions: TLC590, Ropivacaine; Drug
Lead sponsor: TLC Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Bellaire, Texas • Houston, Texas

Conditions: Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Interventions: Velocity Percutaneous Arteriovenous Fistula; Device
Lead sponsor: Venova Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Dothan, Alabama • Concord, California • Riverside, California + 9 more

Conditions: Postoperative Pain
Interventions: EXPAREL, bupivacaine; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 0 Years to 6 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Indianapolis, Indiana • St Louis, Missouri • Durham, North Carolina + 2 more

Conditions: Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
Interventions: Balfaxar, Kcentra; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 3,574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anesthetized Healthy Patients (ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries, Anesthetized Patient With Severe Systemic Disease (ASA 3 or 4)
Interventions: connection of measuring device to anesthesia circuit, drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team, changing operating room bed position (head down and up position), adding PEEP during anesthesia, placement of esophageal Doppler for cardiac output measurements, Humidity sensor, A mixing chamber (bymixer), Pneumotachometer cuvette, Mass spectrometer sampling port; Device · Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Metastatic Breast Cancer
Interventions: AlloStim, Cryoablation; Biological · Procedure
Lead sponsor: Mirror Biologics, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stroke, Acute, Ischemic Stroke, Acute
Interventions: EndovascularThrombectomy, Endovascular thrombectomy with any FDA-approved device; Procedure · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Thoracic Diseases
Interventions: Fiberoptic Endoscopic Evaluation of Swallowing; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Gainesville, Florida

Conditions: Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal
Interventions: Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spine Surgery Complications, Infection
Interventions: Surgical Recovery Support Pillow; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Head and Neck Cancer
Interventions: ABY-029; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Search by objective public record fields.

An Isolation Device to Contain Aerosol During Aerosol Generating Procedures in the Operating Room

Hernia Repair in Multiply Morbid Patients

RNS® System Feasibility Study

Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D

Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

Operative Versus Non-Operative Management for Appendicitis With Abscess or Phlegmon

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

NSS-Bridge Device for Post-Cesarean Delivery Pain

Neoadjuvant Propanolol in Breast Cancer

Percutaneous Excision Trial

A Study on TLC590 for Managing Postsurgical Pain

Pivotal Study of the Velocity™ pAVF System

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Gas Kinetics and Metabolism in Anesthesia During Non Steady State

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

Endovascular Therapy for Large Core Patients With Uncertain Response to Thrombectomy

Dysphagia in Thoracic Surgical Patients

OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)

Surgical Recovery Support Pillow for Spine Surgeries

A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery